TABLE 4.
Pooled estimates of the effect of coenzyme Q10 on inflammatory and stress oxidative biomarkers according to SMD analysis.
| Group | No. of comparisons | SMD (95% CI) | p-value | I 2 (%) | P-heterogeneity |
|---|---|---|---|---|---|
| Q10 supplementation on TNF-α levels | |||||
| Total | 4 | −0.70 (−2.09, 0.68) | 0.320 | 97.8 | <0.001 |
| Age (years) | |||||
| ≤55 | 1 | −0.44 (−0.88, - 0.00) | 0.050 | - | - |
| >55 | 2 | −1.12 (−3.59, 1.34) | 0.371 | 93.0 | <0.001 |
| NR | 1 | −0.11 (−0.50, 0.28) | 0.585 | - | - |
| Duration (week) | |||||
| ≤10 | 1 | −2.30 (−2.49, −2.11) | <0.001 | - | - |
| >10 | 3 | −0.23 (−0.52, 0.05) | 0.110 | 0.0 | 0.428 |
| Dose (mg) | |||||
| ≤200 | 3 | −0.78 (−2.58, 1.01) | 0.392 | 98.1 | <0.001 |
| >200 | 1 | −0.44 (−0.88, −0.00) | 0.050 | - | - |
| Q10 supplementation on IL-6 levels | |||||
| Total | 4 | −0.85 (−1.71, 0.01) | 0.053 | 95.9 | <0.001 |
| Age(years) | |||||
| ≤55 | 1 | −1.56 (−1.73, −1.39) | <0.001 | - | - |
| >55 | 2 | −0.67 (−1.73, 0.38) | 0.211 | 45.6 | 0.175 |
| NR | 1 | −0.24 (−0.63, 0.16) | 0.234 | - | - |
| Duration (weeks) | |||||
| ≤10 | 1 | −1.56 (−1.73, −1.39) | <0.001 | - | - |
| >10 | 3 | −0.35 (−0.61, −0.09) | 0.008 | 11.5 | 0.323 |
| Dose (mg) | |||||
| ≤200 | 3 | −1.06 (−2.17, 0.06) | 0.064 | 94.5 | <0.001 |
| >200 | 1 | −0.37 (−0.65, −0.09) | 0.010 | - | - |
| Q10 supplementation on CRP levels | |||||
| Total | 3 | −0.39 (−0.77, −0.01) | 0.042 | 38.5 | 0.197 |
| Q10 supplementation on MDA levels | |||||
| Total | 9 | −1.17 (−1.55, −0.79) | <0.001 | 62.4 | 0.007 |
| Sample size | |||||
| ≤300 | 5 | −1.36 (−2.17, −0.56) | <0.001 | 60.5 | 0.038 |
| >300 | 4 | −1.15 (−1.65, −0.66) | <0.001 | 73.0 | 0.011 |
| Age (year) | |||||
| ≤55 | 5 | −1.13 (−1.69, −0.57) | <0.001 | 56.4 | 0.057 |
| >55 | 2 | −0.79 (−1.28, −0.31) | <0.001 | 16.2 | 0.275 |
| NR | 2 | −1.84 (−3.42, −0.25) | 0.023 | 84.8 | 0.010 |
| Duration (weeks) | |||||
| ≤10 | 3 | −1.60 (−3.11, −0.09) | 0.038 | 82.3 | 0.004 |
| >10 | 6 | −1.07 (−1.45, −0.70) | <0.001 | 49.8 | 0.076 |
| Dose (mg/day) | |||||
| ≤200 | 8 | −1.16 (−1.55, −0.77) | <0.001 | 66.5 | 0.004 |
| >200 | 1 | −1.57 (−3.61, 047) | 0.131 | - | - |
| Q10 supplementation on TAC levels | |||||
| Total | 6 | 1.21 (0.61, 1.81) | <0.001 | 76.9 | <0.001 |
| Sample size | |||||
| ≤300 | 2 | 0.66 (0.16, 1.16) | 0.010 | 19.4 | 0.265 |
| >300 | 4 | 1.65 (0.67, 2.62) | <0.001 | 83.6 | <0.001 |
| Age (year) | |||||
| ≤55 | 3 | 0.92 (0.13, 1.70) | 0.022 | 77.7 | 0.011 |
| >55 | 1 | 0.84 (0.32, 1.36) | 0.002 | - | - |
| NR | 2 | 2.27 (0.21, 4.34) | 0.031 | 82.9 | 0.016 |
| Duration (weeks) | |||||
| ≤10 | 2 | 1.79 (−1.24, 4.83) | 0.247 | 92.8 | <0.001 |
| >10 | 4 | 1.07 (0.58, 1.56) | <0.001 | 61.2 | 0.052 |
| Dose (mg/day) | |||||
| ≤200 | 4 | 0.73 (0.45, 1.01) | <0.001 | 0.0 | 0.435 |
| >200 | 2 | 2.49 (0.97, 4.01) | <0.001 | 72.5 | 0.057 |
| Q10 supplementation on SOD levels | |||||
| Total | 7 | 1.08 (0.37, 1.79) | 0.003 | 95.7 | <0.001 |
| Sample size | |||||
| ≤200 | 2 | 2.43 (2.14, 2.72) | <0.001 | 0.0 | 0.782 |
| >200 | 5 | 0.48 (0.32, 0.64) | <0.001 | 0.0 | 0.420 |
| Age (year) | |||||
| ≤60 | 2 | 1.45 (−0.46, 3.36) | 0.136 | 97.9 | <0.001 |
| >60 | 3 | 0.62 (0.11, 1.12) | 0.017 | 77.3 | 0.012 |
| NR | 2 | 0.77 (0.26, 1.28) | 0.003 | 33.1 | 0.222 |
| Duration (weeks) | |||||
| ≤10 | 5 | 0.98 (0.06, 1.89) | 0.036 | 96.9 | <0.001 |
| >10 | 2 | 1.49 (−0.46, 3.45) | 0.134 | 85.5 | 0.009 |
| Dose (mg/day) | |||||
| ≤200 | 1 | 2.42 (2.13, 2.72) | <0.001 | - | - |
| >200 | 6 | 0.59 (0.32, 0.87) | <0.001 | 58.8 | 0.033 |
Abbreviation: N, number; NR, not reported.